Fibrosis

Current Location

83 Fibrosis Trials Near You

Power is an online platform that helps thousands of Fibrosis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Atorvastatin + Beta Blockers for Liver Cirrhosis

Charleston, West Virginia
Decompensated cirrhosis (liver disease) occurs when liver function decreases to the extent that serious complications develop and can include internal bleeding, fluid buildup in the abdomen, or mental confusion. This reduced decreased liver function subsequently decreases life expectancy. There is a critical need for strategies to delay progression to decompensation and reduce the occurrence of serious complications. Currently, limited therapeutic options are available for managing decompensated liver disease, with beta-blockers (BB) being the only proven medication with significant benefits in preventing disease progression. Statins have been historically under- prescribed in cirrhosis due to concerns of liver damage. However, there is emerging evidence that statin use may be beneficial and able to lessen liver disease worsening, with studies demonstrating its safety. Thus, we aim to conduct a pilot randomized controlled trial (RCT) study of 50 subjects comparing the outcomes of decompensated cirrhotic patients receiving the statin, atorvastatin, and a non-selective beta-blocker (NSBB) versus those receiving NSBB plus placebo. Both groups will be followed for 12 months to investigate the feasibility, safety, and efficacy of combination therapy.

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2

50 Participants Needed

Nalbuphine ER for Pulmonary Fibrosis

Windsor
This is a multi-center randomized, double-blind, placebo-controlled, parallel, 4-arm study of nalbuphine ER (NAL ER). After meeting eligibility during the Screening Period, subjects will be randomized (1:1:1:1) to one of four treatment arms with placebo and increasing doses of nalbuphine ER. Each arm will be titrated to their fixed dose during the blinded 2-week Titration period followed by the 4-week Fixed Dose Period for a total of 6 weeks on drug. For more information see the country specific approved websites: Germany, Netherlands, Poland, Spain, Italy, Chile: TheCoralTrial.com United Kingdom, Australia, Canada: CoralCoughTrial.com Turkey: please refer to the list of locations and reach out to the site directly

Trial Details

Trial Status:Recruiting

160 Participants Needed

ELX/TEZ/IVA for Cystic Fibrosis

Pittsburgh, Pennsylvania
This trial is testing a combination of three medications to help people with cystic fibrosis. The medications work together to fix a broken protein in the body, which can improve lung function and overall health.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:2+

71 Participants Needed

CGM-Assisted Insulin Dosing for Cystic Fibrosis-Related Diabetes

Pittsburgh, Pennsylvania
The aim of this study is to assess the utility of CGMs to determine the optimal method to dose meal-time insulin. The investigators will examine glucose excursions in patients with CF who will dose meal-time rapid-acting insulin by carbohydrate counting versus fixed-dose rapid-acting insulin. The carbohydrate ratio and fixed doses will be determined by existing doses, total daily insulin doses, body weight, and insulin sensitivity along with predisposition to hypoglycemia. Bolus insulin dosing is an important part of CFRD management due to the high nutritional demands of these patients. If dosed incorrectly, this could lead to marked hyperglycemia and could worsen nutritional status due to urinary glucose losses. In this project, the investigators will perform a within-subjects' comparison of the 2 standard methods of meal-time rapid-acting insulin dosing.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4

13 Participants Needed

RCT2100 for Cystic Fibrosis

Pittsburgh, Pennsylvania
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65

158 Participants Needed

Volara System for Cystic Fibrosis

Pittsburgh, Pennsylvania
This is a small pilot study with the goal of identifying a superior sputum collection method in Cystic Fibrosis patients unable to produce a sputum. Participants will use the Volara System during clinic visit in an attempt to produce sputum.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

20 Participants Needed

Streamlined MRSA Treatment for Cystic Fibrosis

Ann Arbor, Michigan
To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:2 - 45

42 Participants Needed

ENV-101 for Pulmonary Fibrosis

Ann Arbor, Michigan
The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+

200 Participants Needed

GSK3915393 for Pulmonary Fibrosis

Ann Arbor, Michigan
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

150 Participants Needed

Lung and Bone Marrow Transplant for Pulmonary Fibrosis

Pittsburgh, Pennsylvania
The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 60

8 Participants Needed

DWN12088 for Idiopathic Pulmonary Fibrosis

Pittsburgh, Pennsylvania
This trial is testing a new drug called DWN12088 to see if it can help people with Idiopathic Pulmonary Fibrosis, a serious lung disease. The study will check if the drug is safe and effective. The exact way the drug works is not detailed, but it aims to improve lung function or slow down the disease.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+

102 Participants Needed

EGCG for Pulmonary Fibrosis

Ann Arbor, Michigan
This trial is testing EGCG, a compound from green tea, in patients with idiopathic pulmonary fibrosis (IPF). The goal is to see if EGCG can safely reduce lung scarring. EGCG works by blocking harmful signals that cause lung tissue to harden. Epigallocatechin-3-gallate (EGCG) is a polyphenol and a major component of green tea, known for its potent antioxidant, anti-inflammatory, and anti-fibrotic properties.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:40 - 85

50 Participants Needed

EGCG for Pulmonary Fibrosis

Ann Arbor, Michigan
The primary purpose of this substudy is to determine if collagen-targeted PET using the type 1 collagen-targeted PET probe, Gallium-68 (68Ga)-labeled collagen binding probe 8 (CBP8) can inform as to drug effect of EGCG and assist in dose selection.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:40 - 85

22 Participants Needed

Sinonasal Therapies for Cystic Fibrosis

Indianapolis, Indiana
The investigators are doing this study to discover if it is appropriate for people with Cystic Fibrosis (CF) on highly effective modulator therapy (HEMT) to stop using certain standard Sino nasal therapies such as high-volume nasal saline irrigations, topical nasal steroids, and topical nasal antibiotics. They are also going to study the fluid inside the nose to see if there are changes when stopping these therapies. Right now, they are not sure if it is suggested to stop these treatments when patients begin highly effective modulator therapy (HEMT)
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 3

64 Participants Needed

Smartphone Evaluation for Airway Diseases

Pittsburgh, Pennsylvania
The study will evaluate the feasibility of using smartphone speakers and microphones to evaluate the caliber of the airways, detect airway obstruction, aid in airway disease diagnosis, and identify disease exacerbations.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:8 - 65

800 Participants Needed

Biomarker Screening for Liver Cancer

Detroit, Michigan
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), and HCC etiology (viral vs. non-viral). Patients will be recruited from 15 sites (mix of tertiary care and large community health systems) over a 3-year period, and the primary endpoint of the phase IV trial, reduction in late-stage HCC, will be assessed after 5.5 years.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

5500 Participants Needed

Ensifentrine for Bronchiectasis

Ann Arbor, Michigan
This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

180 Participants Needed

Lactulose + TeleTai-Chi for Liver Cirrhosis

Ann Arbor, Michigan
This multicenter trial is being conducted to determine if sequential lactulose and Tele (virtual) Tai-Chi reduces the rate of injurious fall, non-injurious falls, incident overt Hepatic Encephalopathy (HE), and death or liver transplant over 24 weeks. Participants that are enrolled will be randomized to stage one of this project for approximately 12 weeks. After completing stage one, participants will be re-randomized to stage 2 of the project that will last approximately 12 more weeks. The study hypothesizes that sequential lactulose/TeleTai-Chi will reduce falls, incident overt HE, death and physical frailty and will improve cognitive function, and Health Related Quality of Life (HRQOL) over 24 weeks compared to other treatment combinations.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

430 Participants Needed

Electrical Stimulation for Pain and Depression in Liver Cirrhosis

Ann Arbor, Michigan
This study is being done to better understand how the study team can treat pain for people with cirrhosis and depression. Enrolled participants on this feasibility study will be randomized to Transcutaneous Electrical Acustimulation (TEA) or sham TEA.

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

30 Participants Needed

Saroglitazar for Liver Cirrhosis

Indianapolis, Indiana
A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

30 Participants Needed

Why Other Patients Applied

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

Resistant Potato Starch for Liver Cirrhosis

Ann Arbor, Michigan
This research is studying how a food product (resistant potato starch) which is a dietary supplement made from potato starch affects the gut bacteria of people with cirrhosis and hepatic encephalopathy. The researchers in this study want to understand how potato starch works in the subject's body and how the body will react to it. Along with taking the study product participants health-related information and stool will be collected for this research study.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

20 Participants Needed

ALN-HSD for NASH with Fibrosis

Indianapolis, Indiana
This trial is testing a new drug called ALN-HSD to help people with a liver disease called NASH. NASH causes fat to build up in the liver, leading to damage and scarring. The drug aims to reduce this damage and improve liver health.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

90 Participants Needed

LY3849891 for Non-alcoholic Fatty Liver Disease

Indianapolis, Indiana
This trial is testing a new medication called LY3849891 in people with fatty liver disease who have a specific genetic variant. The study will check how the drug affects liver fat and how the body processes it using blood tests and imaging.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

176 Participants Needed

123

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Fibrosis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Fibrosis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Fibrosis trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Fibrosis is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Fibrosis medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Fibrosis clinical trials?

Most recently, we added Sinonasal Therapies for Cystic Fibrosis, Electrical Stimulation for Pain and Depression in Liver Cirrhosis and Drug-Releasing Cochlear Implant for Hearing Loss to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Liver Fibrosis Clinical Trials

Top Pulmonary Fibrosis Clinical Trials

Top Cystic Fibrosis Clinical Trials

Top Idiopathic Pulmonary Fibrosis Clinical Trials

174 Clinical Trials near Clearwater, FL

189 Clinical Trials near Gretna, LA

174 Clinical Trials near Brownsville, TX

109 Clinical Trials near St. Louis Park, MN

Top Hyperthermia Clinical Trials

Top Preeclampsia Clinical Trials

Top Neurofibromatosis Clinical Trials

Top Myopia Clinical Trials

By Trial

One-Legged vs Two-Legged Cycle Training for Idiopathic Pulmonary Fibrosis

Tocopherol + Pravastatin + Pentoxifylline for Radiation-Induced Lymphedema and Fibrosis

Ceftaroline for Cystic Fibrosis

VX-522 mRNA Therapy for Cystic Fibrosis

Zinc + Nicotinamide Riboside for Pulmonary Fibrosis

Semaglutide for Cystic Fibrosis-Related Diabetes

Atorvastatin for Liver Cancer Risk in Fibrosis

Elastography for Primary Sclerosing Cholangitis

Trikafta for Bronchiectasis

Ultrasound for Erectile Dysfunction

Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis

AI-Enabled ECG for Liver Disease

Related Searches

Top Heart-attack Clinical Trials

Top Bronchiolitis Clinical Trials

Top Cerebellar-ataxia Clinical Trials

Transcutaneous Auricular Neurostimulation for Alcohol Withdrawal

PDM Alert for Postoperative Delirium

Ruxolitinib for Lung Dysfunction Post Stem Cell Transplant

iBreastExam Device for Breast Cancer Screening

Linerixibat for Itching in Cholangitis

Smoking Cessation Program for Caregivers Who Smoke

Nivolumab + Chemo-Immunotherapy for Large B-Cell Lymphoma

CD123 Redirected T Cells for Leukemia

BAC-Enhanced Information Sharing for Mammogram Screening

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial